Zobrazeno 1 - 10
of 342
pro vyhledávání: '"Kathy S Albain"'
Autor:
Julie E. Lang, Andres Forero-Torres, Douglas Yee, Christina Yau, Denise Wolf, John Park, Barbara A. Parker, A. Jo Chien, Anne M. Wallace, Rashmi Murthy, Kathy S. Albain, Erin D. Ellis, Heather Beckwith, Barbara B. Haley, Anthony D. Elias, Judy C. Boughey, Rachel L. Yung, Claudine Isaacs, Amy S. Clark, Hyo S. Han, Rita Nanda, Qamar J. Khan, Kristen K. Edmiston, Erica Stringer-Reasor, Elissa Price, Bonnie Joe, Minetta C. Liu, Lamorna Brown-Swigart, Emanuel F. Petricoin, Julia D. Wulfkuhle, Meredith Buxton, Julia L. Clennell, Ashish Sanil, Scott Berry, Smita M. Asare, Amy Wilson, Gillian L. Hirst, Ruby Singhrao, Adam L. Asare, Jeffrey B. Matthews, Michelle Melisko, Jane Perlmutter, Hope S. Rugo, W. Fraser Symmans, Laura J. van ‘t Veer, Nola M. Hylton, Angela M. DeMichele, Donald A. Berry, Laura J. Esserman
Publikováno v:
npj Breast Cancer, Vol 8, Iss 1, Pp 1-10 (2022)
Abstract HSP90 inhibitors destabilize oncoproteins associated with cell cycle, angiogenesis, RAS-MAPK activity, histone modification, kinases and growth factors. We evaluated the HSP90-inhibitor ganetespib in combination with standard chemotherapy in
Externí odkaz:
https://doaj.org/article/f1ec1969e2aa401dafdcc1102c26a20e
Autor:
Amy S. Clark, Christina Yau, Denise M. Wolf, Emanuel F. Petricoin, Laura J. van ‘t Veer, Douglas Yee, Stacy L. Moulder, Anne M. Wallace, A. Jo Chien, Claudine Isaacs, Judy C. Boughey, Kathy S. Albain, Kathleen Kemmer, Barbara B. Haley, Hyo S. Han, Andres Forero-Torres, Anthony Elias, Julie E. Lang, Erin D. Ellis, Rachel Yung, Debu Tripathy, Rita Nanda, Julia D. Wulfkuhle, Lamorna Brown-Swigart, Rosa I. Gallagher, Teresa Helsten, Erin Roesch, Cheryl A. Ewing, Michael Alvarado, Erin P. Crane, Meredith Buxton, Julia L. Clennell, Melissa Paoloni, Smita M. Asare, Amy Wilson, Gillian L. Hirst, Ruby Singhrao, Katherine Steeg, Adam Asare, Jeffrey B. Matthews, Scott Berry, Ashish Sanil, Michelle Melisko, Jane Perlmutter, Hope S. Rugo, Richard B. Schwab, W. Fraser Symmans, Nola M. Hylton, Donald A. Berry, Laura J. Esserman, Angela M. DeMichele
Publikováno v:
Nature Communications, Vol 12, Iss 1, Pp 1-11 (2021)
HER2-targeted therapy improves patient’s outcome in early breast cancer. Here, the authors present the efficacy and biomarker analysis of two HER2-targeted combinations (ado-trastuzumab emtansine plus pertuzumab and paclitaxel, trastuzumab and pert
Externí odkaz:
https://doaj.org/article/e6340916dac6476fac8b24ed5afd32c1
Autor:
Douglas Yee, Claudine Isaacs, Denise M. Wolf, Christina Yau, Paul Haluska, Karthik V. Giridhar, Andres Forero-Torres, A. Jo Chien, Anne M. Wallace, Lajos Pusztai, Kathy S. Albain, Erin D. Ellis, Heather Beckwith, Barbara B. Haley, Anthony D. Elias, Judy C. Boughey, Kathleen Kemmer, Rachel L. Yung, Paula R. Pohlmann, Debu Tripathy, Amy S. Clark, Hyo S. Han, Rita Nanda, Qamar J. Khan, Kristen K. Edmiston, Emanuel F. Petricoin, Erica Stringer-Reasor, Carla I. Falkson, Melanie Majure, Rita A. Mukhtar, Teresa L. Helsten, Stacy L. Moulder, Patricia A. Robinson, Julia D. Wulfkuhle, Lamorna Brown-Swigart, Meredith Buxton, Julia L. Clennell, Melissa Paoloni, Ashish Sanil, Scott Berry, Smita M. Asare, Amy Wilson, Gillian L. Hirst, Ruby Singhrao, Adam L. Asare, Jeffrey B. Matthews, Nola M. Hylton, Angela DeMichele, Michelle Melisko, Jane Perlmutter, Hope S. Rugo, W. Fraser Symmans, Laura J. van‘t Veer, Donald A. Berry, Laura J. Esserman
Publikováno v:
npj Breast Cancer, Vol 7, Iss 1, Pp 1-8 (2021)
Abstract I-SPY2 is an adaptively randomized phase 2 clinical trial evaluating novel agents in combination with standard-of-care paclitaxel followed by doxorubicin and cyclophosphamide in the neoadjuvant treatment of breast cancer. Ganitumab is a mono
Externí odkaz:
https://doaj.org/article/784de0fabd374658a9d09088fa4a5ee8
Autor:
Jennifer M. Mongiovi, Gary R. Zirpoli, Rikki Cannioto, Lara E. Sucheston-Campbell, Dawn L. Hershman, Joseph M. Unger, Halle C. F. Moore, James A. Stewart, Claudine Isaacs, Timothy J. Hobday, Muhammad Salim, Gabriel N. Hortobagyi, Julie R. Gralow, G. Thomas Budd, Kathy S. Albain, Christine B. Ambrosone, Susan E. McCann
Publikováno v:
Breast Cancer Research, Vol 20, Iss 1, Pp 1-12 (2018)
Abstract Background The pathophysiology of chemotherapy-induced peripheral neuropathy (CIPN) is not well understood. Currently, dose reduction is the only recommendation for alleviating symptoms, often leading to premature treatment cessation. The pr
Externí odkaz:
https://doaj.org/article/9d0a7a1284e54998b733c15ed2ca4e29
Autor:
Corey W. Speers, W. Fraser Symmans, William E. Barlow, Alex Trevarton, Stephanie The, Lili Du, James M. Rae, Steven Shak, Rick Baehner, Priyanka Sharma, Lajos Pusztai, Gabriel N. Hortobagyi, Daniel F. Hayes, Kathy S. Albain, Andrew Godwin, Alastair Thompson
Publikováno v:
Journal of Clinical Oncology. 41:1841-1848
PURPOSE Chemotherapy has not demonstrated benefit over adjuvant endocrine therapy alone for postmenopausal patients with node-positive breast cancer with a 21-gene breast recurrence score (RS) of 25 or below (RS ≤ 25). We tested whether combined re
Autor:
Yuli Chen, William E. Barlow, Haojia Li, Cheng Lu, Andrew Janowczyk, German Corredor, Shridar Ganesan, Michael Feldman, Pingfu Fu, Hannah Gilmore, Kathy S. Albain, Lajos Pusztai, James Rae, Daniel Hayes, Andrew K. Godwin, Alastair M. Thompson, Anant Madabhushi
Publikováno v:
Cancer Research. 83:P2-11
Background: Lymph node (LN) involvement is a strong indicator of poor prognosis for breast cancer (BC), with adjuvant chemotherapy remaining fundamental to management of these patients. SWOG S8814 was a Phase III randomized trial of postmenopausal pa
Autor:
Joseph Sparano, Robert J. Gray, Della Makower, Kathy S. Albain, Daniel F. Hayes, Charles Geyer, Elizabeth Dees, Matthew P. Goetz, John A. Olson, Tracy G. Lively, Sunil Badve, Thomas Saphner, Lynne I. Wagner, Timothy Whelan, Virginia Kaklamani, George Sledge
Publikováno v:
Cancer Research. 83:GS1-05
Background: Late recurrence of breast cancer after 5 years accounts for about 50% of recurrences in hormone receptor (HR)-positive early breast cancer (EBC). TAILORx established non-inferiority of adjuvant endocrine therapy (ET) given for at least 5
Autor:
Irene Kang, Jamie K. Forschmiedt, Michelle M. Loch, William E. Barlow, Danika L. Lew, Julie R. Gralow, Funda Meric-Bernstam, Kathy S. Albain, Daniel F. Hayes, Nancy U. Lin, Edith A. Perez, Lori J. Goldstein, Priya Rastogi, Anne F. Schott, Steven Shak, Priyanka Sharma, Jieling Miao, Debu Tripathy, Lajos Pusztai, Gabriel N. Hortobagyi, Kevin Kalinsky, N. Lynn Henry
Publikováno v:
Cancer Research. 83:GS1-04
Introduction: Breast cancer treatment is associated with cancer-related cognitive impairment (CRCI). However, the differential effect of endocrine therapy (ET) vs chemotherapy followed by endocrine therapy (CET), including the impact of menopausal st
Autor:
Sara M Tolaney, Paolo Tarantino, Noah Graham, Nabihah Tayob, Laia Parè, Guillermo Villacampa, Chau T Dang, Denise A Yardley, Beverly Moy, P Kelly Marcom, Kathy S Albain, Hope S Rugo, Matthew J Ellis, Iuliana Shapira, Antonio C Wolff, Lisa A Carey, Romualdo Barroso-Sousa, Patricia Villagrasa, Michelle DeMeo, Molly DiLullo, Jorge Gomez Tejeda Zanudo, Jakob Weiss, Nikhil Wagle, Ann H Partridge, Adrienne G Waks, Clifford A Hudis, Ian E Krop, Harold J Burstein, Aleix Prat, Eric P Winer
Publikováno v:
The Lancet Oncology. 24:273-285
Autor:
Daniel Shao, William E. Barlow, Haojia Li, Cheng Lu, Kathy S. Albain, James Rae, Daniel F. Hayes, Andrew K. Godwin, Alastair M. Thompson, Anant Madabhushi, Lajos Pusztai
Publikováno v:
Cancer Research. 83:P2-11
Background: Adjuvant chemotherapy is a common treatment for breast cancer patients with aggressive tumors, but imposes severe side effects. Although lymph node involvement is associated with higher likelihood of mortality, a subset of LN+ patients ca